Atyr Pharma, Inc. · NASDAQ:ATYR
Atyr Pharma — Corporate Update (May 2026)
12 slides from Atyr Pharma's corporate update, May 11, 2026
Slide 1: Efzofitimod in Pulmonary Sarcoidosis and Beyond
aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,”
Slide 3: FDA Type C Meeting Informs Future Efzofitimod Development
FDA Type C Meeting Informs Future Efzofitimod Development Background EFZO-FIT missed its primary endpoint but demonstrated a safety profile consistent with previous trials and durable benefit on multiple clinically meaningful, prespecified quality of life measures aTyr was granted a Type C meeting t
Slide 4: FDA Type C Meeting Informs Future Efzofitimod Development
FDA Type C Meeting Informs Future Efzofitimod Development FDA indicated support for FVC and KSQ-L as clinically meaningful endpoints in pulmonary sarcoidosis FDA indicated FVC to be a direct measure of how patients function FDA indicated KSQ-L to be a direct measure of how patients feel, and recomme
Slide 5: Sarcoidosis has Heterogenous Lung Phenotypes; FVC Relevant Only in Restrictive Phenotype
Sarcoidosis has Heterogenous Lung Phenotypes; FVC Relevant Only in Restrictive Phenotype EFZO-FIT DATA EFZO-FIT enrolled all pulmonary phenotypes; C-006 will create a more homogenous patient population by focusing on one lung phenotype *Sharp M, et al. Ann Am Thorac Soc. 2023 Jan;20(1):30-37. †Need
Slide 6: Data from EFZO-FIT Support Our Rationale for FVC as Primary Endpoint
Data from EFZO-FIT Support Our Rationale for FVC as Primary Endpoint in Target Patient Population EFZO-FIT DATA Clinically meaningful benefit observed for FVC in patients with restrictive lung disease when treated with efzofitimod W48 window ends on Study Day 351. *Not Restrictive: includes normal,
Slide 7: FDA Type C Meeting Informs Future Efzofitimod Development
FDA Type C Meeting Informs Future Efzofitimod Development FDA acknowledged reasonableness of the proposed Q3W dosing in the proposed patient population in C-006 Aligned with FDA on incorporating additional risk mitigation strategies in the protocol Safety surveillance for the potential for developme
Slide 8: Go-Forward Development Plan Leverages Insights from EFZO-FIT and Engagement with FDA
Go-Forward Development Plan Leverages Insights from EFZO-FIT and Engagement with FDA ATYR1923-C-006 Study design to incorporate key changes intended to demonstrate compelling evidence of efficacy and safety on clinically meaningful endpoint Abbreviations: FVC, forced vital capacity; Q3W, every three
Slide 9: ATYR1923-C-006 Phase 3 Study Design
Continue on stable background therapy (OCS 0 to ≤5 mg/d) Continue on stable background IS Screening A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate Efzofitimod in Patients with Pulmonary Sarcoidosis Target Population: Moderate to severe pulmonary sarcoidosis with restrictive d
Slide 10: Proposed Key Inclusion and Exclusion Criteria
Proposed Key Inclusion and Exclusion Criteria ATYR1923-C-006 Study focuses on the right patients for the right endpoints Abbreviations: DLCOpp, diffusing capacity of the lungs for carbon monoxide, percent predicted; FEV1, forced expiratory volume in 1 second; FVCpp, forced vital capacity, percent pr
Slide 11: US Pulmonary Sarcoidosis Target Population: ILD Without Advanced Fibrosis
*<80% FVCpp; FEV1/FVC ≥0.7. †>20% on HRCT; †Diagnosed pulmonary means ICD10 code D86.0 or D86.2. Sharp M, et al. Ann Am Thorac Soc. 2023 Jan;20(1):30-37; Obi O, et al. Chest. 2024 Apr; 165(4):892-907. Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HRCT, high-r
Slide 12: Thank You
12 | ©2026 aTyr Pharma Thank You